USD 6.10 billion
Report ID:
SQMIG35H2263 |
Region:
Global |
Published Date: September, 2024
Pages:
210
|Tables:
0
|Figures:
0
Global Radiopharmaceuticals Market size was valued at USD 6.10 billion in 2022 and is poised to grow from USD 6.7 billion in 2023 to USD 8.00 billion by 2031, growing at a CAGR of 9.8% in the forecast period (2024-2031).
Advances in imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) have revolutionized diagnostic capabilities in healthcare. These techniques rely on radiopharmaceuticals to complement traditional anatomy in imaging modalities such as CT, MRI and others with improved specificity and sensitivity. The development of radiotracers has increased the diagnostic accuracy, thus chronic diseases Provides early diagnosis and accurate characterization. For example, in June 2023, GE Healthcare announced the launch of the world’s first investigational PET nuclear imaging product to detect and predict response to cancer immunotherapies.
For example, the world is seeing a dramatic increase in the prevalence of chronic conditions such as cancer, Alzheimer's disease and heart disease. For example, 299,000 new cases of prostate cancer are expected in the US. by 2024, according to the American Cancer Society’s projection released in January 2024. Furthermore, the same data shows that about 1 in 8 men are diagnosed with prostate cancer each year in the US. Furthermore, according to a study published by the Alzheimer's Association in April 2024, there are currently 6.9 million Americans over the age of 65 suffering from the disease and this number is projected to rise to 13.8 million by 2060. It is expected that such high prevalence of chronic conditions would create profitable market growth opportunities.
Global Market Size
USD 6.10 billion
Largest Segment
Diagnostic Nuclear Medicine
Fastest Growth
Bone Scans
Growth Rate
9.8% CAGR
To get more reports on the above market click here to Buy The Report
Based on Type the market is segmented as, Diagnostic Nuclear Medicine, SPECT Radiopharmaceuticals, Technetium-99m, Thallium-201, Gallium-67, Iodine-123, Other, PET Radiopharmaceuticals, F-18, RU-82, Others, Therapeutic Nuclear Medicine, Alpha Emitters, Ra-223, Brachytherapy Isotopes, Intoiodine-125, Palladium-103, Cesium-131, Iridium-192, Other brachytherapy isotopes, Beta Emitters, Intoiodine-131, Yttrium-90, Samarium-153, Lutetium-177, Rhenium-186, Other beta emitters. Based on Application the market is segmented as, Diagnostic Applications, SPECT Applications, Cardiology, Bone Scans, Thyroid Applications, Pulmonary Scans, Other SPECT Applications, PET applications, Oncology, Cardiology, Neurology, Other PET applications, Therapeutic Applications, Thyroid Indications, Bone Metastasis, Lymphoma, Endocrine Tumors, Other Indications. Based on Procedural Volume Assessment the market is segmented as, Diagnostic Procedures, Therapeutic Procedures. Based on Source the market is segmented as, Nuclear Reactors, Cyclotrons. Based on End User the market is segmented as, Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes, Others. Based on Region the market is segmented as, North America, U.S., Canada, Mexico, Europe, Germany, France, UK, Italy, Spain, Rest of Europe, Asia-Pacific, Japan, China, Australia, India, Rest of Asia-Pacific, LAMEA, Brazil, Saudi Arabia, South Africa, Rest of LAMEA.
Analysis by End User
Hospitals play an important role in the radiopharmaceuticals market as it is a major hub for diagnostic and therapeutic imaging. Hospitals are major users of radiopharmaceuticals where radiopharmaceuticals are used extensively for targeted therapy due to the availability of advanced medical imaging tools such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed). Therefore, the ability of hospitals to provide comprehensive care by consuming state-of-the-art radiopharmaceutical therapy role is crucial for their market growth
Ambulatory surgical centers (ASCs) also contribute significantly to the radiopharmaceuticals market by providing outpatient imaging and treatment services. ASCs offer a cost-effective and convenient option for patients requiring radiopharmaceutical modalities, especially in diagnostic imaging. The increase in outpatient care and the increasing demand for minimally invasive therapies have made ASC attractive for radiopharmaceutical applications, especially in the early detection of cancer and the diagnosis of cardiomyopathy. The increasing adoption of their radiopharmaceutical technology is helping to expand the market beyond traditional clinical settings.
Analysis by Application
Diagnostic applications play an important role in the radiopharmaceuticals market, especially using imaging techniques such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) for the detection and monitoring of biological processes. The molecular level diagnosis of various infectious diseases is possible, which is critical to improve clinical outcomes. The increasing demand for early diagnosis and advances in molecular imaging technologies are driving the use of radiopharmaceuticals in diagnostic applications
SPECT (Single Photon Emission Computed Tomography) applications are an important segment of the radiopharmaceuticals market, providing advanced imaging for various conditions, especially in cardiology, neurology and oncology. SPECT imaging uses gamma-emitting radiopharmaceuticals to create 3D images, blood flow, organ function. The technique also provides detailed information about cell function and is particularly effective in detecting conditions such as coronary artery disease, Alzheimer’s disease and some cancers.
The ability of SPECT to provide functional information at a lower cost compared to PET has made it widely available, especially in emerging markets. The increasing use of SPECT in cardiac stress testing and brain imaging is driving the growth of this segment. With continued improvements in SPECT technology, including hybrid systems that combine SPECT and CT imaging for better diagnosis, the application of SPECT in the radiopharmaceuticals market is expected to expand further.
To get detailed analysis on other segments, Request For Free Sample Report
North America occupies a dominant position in the radiopharmaceuticals market, driven primarily by strong healthcare infrastructure, a well-established pharmaceutical industry, and large investments in R&D. Increased focus on personalized medicine and early diagnosis of diseases also contributes to the growth of the market in North America. U.S. is a key country, with most of the market share in the region due to leading pharmaceutical companies, advanced medical imaging technology, high prevalence of cancer. With the presence of key medical specialists and well-funded research institutes, the North America region is expected to continue to dominate the radiopharmaceuticals market share.
Asia-Pacific is emerging as an important market for radiopharmaceuticals, driven by rapidly developing healthcare infrastructure, increasing awareness of nuclear medicine and rising healthcare costs. It underscores the need for s In Asia-Pacific, too, governments are investing in nuclear medicine, and regional players are expanding their radiopharmaceutical manufacturing. The availability of more patients leading to advanced healthcare positions Asia Pacific as a radiopharmaceuticals market size growing in the coming years. The APAC region is expected to grow the fastest globally due to increasing awareness among individuals and increasing number of diagnoses. This in turn will increase the demand for SPECT and PET equipment. Another factor expected to increase expansion over the forecast period is the increase in the number of healthcare facilities and the improvement in the quality of care. Most of the countries in the region are developing countries they are making progress, working towards a more robust and effective healthcare system. Thus, they offer excellent opportunities to sell radiopharmaceutical products, which are highly profitable in the length and breadth of the healthcare sector.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Drivers
Growing Demand for Cancer Treatment
Technological Advances in Imaging Techniques
Restraints
Strict Legal Requirements
High Cost of Radiopharmaceuticals
Request Free Customization of this report to help us to meet your business objectives.
The global radiopharmaceuticals market features a highly competitive landscape with several key players vying for market share. A notable example of cooperation in the radiopharmaceuticals market is the collaboration between Novartis and Advanced Accelerator Applications (AAA). Novartis acquired AAA, a leading molecular nuclear medicine company. This partnership allowed Novartis to strengthen its position in the radiopharmaceutical industry, especially with the development of targeted therapies for cancer. AAA theranostics (treatment discovery) expertise helped Novartis' oncology portfolio, especially with radiopharmaceutical agents such as Lutathera, which targets neuroendocrine tumors.
Top Player’s Company Profiles
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to SkyQuest analysis, radiopharmaceuticals market is experiencing significant growth, driven by increasing demand for cancer diagnosis and treatment, and advances in imaging technology. Radiopharmaceuticals play an important role in targeted therapy, especially in oncology, cardiology and neurology, provides diagnostic and therapeutic accuracy with minimal side effects. However, the market faces challenges such as stringent regulatory requirements, high costs associated with the development and manufacture of radiopharmaceuticals. Companies overcome these obstacles by strategic planning, acquisitions and joint ventures for their expansion production and market penetration. Emerging trends such as personalized medicine and treatment (combined with diagnostics) are expected to further drive the market growth, providing new opportunities for growth. With key players investing in new products and expanding their global footprint, the radiopharmaceuticals market is poised for strong expansion in the coming years.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 6.10 billion |
Market size value in 2031 | USD 8.00 billion |
Growth Rate | 9.8% |
Base year | 2023 |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Radiopharmaceuticals Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Radiopharmaceuticals Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Radiopharmaceuticals Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Radiopharmaceuticals Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATIONWant to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35H2263